ReLive Biotechnologies Announces NDA Approval of SpheChon 10-70 spheroids/cm² by the HSA in Singapore, Marking a Milestone in ReLive’s Global Endeavors
This approval is a testament to ReLive's commitment to advancing regenerative cell therapies and marks a significant step in expanding our global reach.
- This approval is a testament to ReLive's commitment to advancing regenerative cell therapies and marks a significant step in expanding our global reach.
- SpheChon represents a major advancement in cell therapy for cartilage repair, offering new hope and enhanced treatment options by using the patients’ own cells to regain an active life.
- This approval by HSA reflects ReLive’s dedication to upholding the highest standards of safety, efficacy, and quality in our innovative treatment solutions.
- Quote from ReLive’s CEO, Dr. Xing Zhao: “The approval in Singapore is more than just a regulatory milestone.